publication . Article . 2020

MGMT methylation may benefit overall survival in patients with moderately vascularized glioblastomas

Elies Fuster-Garcia; David Lorente Estellés; María Del Mar Álvarez-Torres; Javier Juan-Albarracín; Eduard Chelebian; Alex Rovira; Cristina Auger Acosta; Jose Pineda; Laura Oleaga; Enrique Mollà-Olmos; ...
Open Access English
  • Published: 01 Oct 2020 Journal: European Radiology, volume 31, issue 3, pages 1,738-1,747 (issn: 0938-7994, eissn: 1432-1084, Copyright policy)
Abstract
Abstract Objectives To assess the combined role of tumor vascularity, estimated from perfusion MRI, and MGMT methylation status on overall survival (OS) in patients with glioblastoma. Methods A multicentric international dataset including 96 patients from NCT03439332 clinical study were used to study the prognostic relationships between MGMT and perfusion markers. Relative cerebral blood volume (rCBV) in the most vascularized tumor regions was automatically obtained from preoperative MRIs using ONCOhabitats online analysis service. Cox survival regression models and stratification strategies were conducted to define a subpopulation that is particularly favored ...
Persistent Identifiers
Subjects
free text keywords: Radiology Nuclear Medicine and imaging, General Medicine, Oncology, Perfusion imaging, Glioblastoma, O(6)-Methylguanine-DNA methyltransferase, Prognostic factors, Temozolomide, Overall survival, In patient, O-6-methylguanine-DNA methyltransferase, Mgmt methylation, Neuroradiology, Perfusion scanning, Perfusion, Temozolomide, medicine.drug, medicine, Internal medicine, medicine.medical_specialty, Oncology, business.industry, business, Radiology, Glioblastoma
Related Organizations
Funded by
EC| ImPRESS
Project
ImPRESS
Imaging Perfusion Restrictions from Extracellular Solid Stress
  • Funder: European Commission (EC)
  • Project Code: 758657
  • Funding stream: H2020 | ERC | ERC-STG
Validated by funder
,
EC| GLIOHAB
Project
GLIOHAB
Multiparametric imaging of glioblastoma tumour heterogeneity for supporting treatment decisions and accurate prognostic estimation
  • Funder: European Commission (EC)
  • Project Code: 844646
  • Funding stream: H2020 | MSCA-IF-EF-ST
Validated by funder
Download fromView all 5 versions
Open Access
ZENODO
Article . 2020
Provider: ZENODO
Open Access
OpenAIRE
Article . 2020
Provider: OpenAIRE
Any information missing or wrong?Report an Issue